323 related articles for article (PubMed ID: 17064996)
21. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
23. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
24. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.
Drapkin R; Di Bella NJ; Faragher DC; Harden E; Matei C; Hyman W; Mirabel M; Boehm KA; Asmar L
Clin Lymphoma; 2003 Dec; 4(3):169-75. PubMed ID: 14715099
[TBL] [Abstract][Full Text] [Related]
25. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
Cánovas A; Alonso JJ; Barreiro G; Aguirre C
Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
[TBL] [Abstract][Full Text] [Related]
28. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
29. Rituximab: an innovative therapy for non-Hodgkin's lymphoma.
Wood AM
Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177
[TBL] [Abstract][Full Text] [Related]
30. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
31. Follicular lymphoma: 2011 update on diagnosis and management.
Freedman A
Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
33. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
[TBL] [Abstract][Full Text] [Related]
34. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
[TBL] [Abstract][Full Text] [Related]
35. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
[TBL] [Abstract][Full Text] [Related]
36. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
37. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
38. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
39. Primary duodenal follicular lymphoma successfully treated with rituximab.
Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
[TBL] [Abstract][Full Text] [Related]
40. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
